Neuronascent has discovered and is developing novel, noninvasive “neurorestorative” therapeutics for Alzheimer's and other CNS disorders
Neuronascent (NNI), founded by Dr. Kelleher-Andersson began operations in 2005. Through NNI's phenotypic screening platform agents were identified that promote mature new neurons. Patents covering NNI's oral therapies are issued. NNI-362, an Alzheimer's candidate has shown reversal of cognitive deficits correlating to increased new neurons in animal models. NNI aims to quickly complete FDA-mandated safety studies with continued support of NIA.